You are here: All Products  > CANbridge Says C5 mAb Effective in Early Trial for Complement Diseases

CANbridge Says C5 mAb Effective in Early Trial for Complement Diseases

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.